Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England
First patients implanted with Genio at UCLH, London
Read more »
Informations sur le nombre total de droits de vote et d'actions
Informations sur le nombre total de droits de vote et d'actions
INFORMATION RÉGLEMENTÉE
Informations [...] Read more »
Information on the total number of voting rights and shares
REGULATED INFORMATION
Information on the total number of voting rights and shares
Mont–Saint–Guibert [...] Read more »
Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference
Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference
Mont–Saint–Guibert, Belgium – [...] Read more »
Nyxoah Participera à la Piper Sandler 36th Annual Healthcare Conference
Nyxoah Participera à la Piper Sandler 36th Annual Healthcare Conference
Nyxoah Participera à la Piper Sandler [...] Read more »
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
- Recursion unveils post–combination technology–enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs
- Platform will focus on first [...] Read more »
Invitation à assister à l'assemblée générale spéciale des actionnaires de la Société qui se tiendra le 19 décembre 2024
INFORMATIONS RÉGLEMENTÉES
le 19 novembre 2024, 7:00h CET / 1:00h ET
NYXOAH SA
(Euronext Brussels/Nasdaq: NYXH)
Rue Edouard Belin 12, 1435 [...] Read more »
Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024
REGULATED INFORMATION
November 19, 2024, 7:00am CET / 1:00am ET
NYXOAH SA
(Euronext Brussels/Nasdaq: NYXH)
Rue Edouard Belin 12, 1435 [...] Read more »
Publication relative à des notifications de transparence
Publication relating to transparency notifications
REGULATED INFORMATION
Publication relating to transparency notifications
Read more »
Synchronoss renouvelle son partenariat avec un opérateur français de premier plan
BRIDGEWATER, New Jersey, 12 nov. 2024 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (« Synchronoss » ou la « Société ») (NASDAQ : SNCR), un innovateur [...] Read more »
Synchronoss Renova Parceria com Grande Operadora Francesa
BRIDGEWATER, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) — A Synchronoss Technologies, Inc. (“Synchronoss” ou a “Empresa”) (Nasdaq: SNCR), líder global e inovadora em plataformas de nuvens [...] Read more »
Synchronoss erneuert Partnerschaft mit großem französischen Betreiber
BRIDGEWATER, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. („Synchronoss“ oder das „Unternehmen“) (NASDAQ: SNCR), ein weltweit führender Anbieter und Innovator im [...] Read more »
Synchronoss Renews Partnership with Major French Operator
BRIDGEWATER, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (NASDAQ: SNCR), a global leader and innovator in personal cloud platforms, today [...] Read more »
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today [...] Read more »